2 results match your criteria: "Panyu Cancer Institute[Affiliation]"
Front Oncol
January 2023
Department of Gynecology, Guangzhou Panyu Central Hospital, Panyu Cancer Institute, Guangzhou, Guangdong, China.
Introduction: Platinum-based combination chemotherapy is recommended first choice for relapsed ovarian cancer. However, many of the chemotherapeutic agents are nephrotoxic and can promote kidney dysfunction, which affect the efficacy of cancer treatment and the survival of the patient. There is a need to explore long-term treatments of chemotherapy-free regimen of chronic kidney disease in recurrent ovarian cancer.
View Article and Find Full Text PDFMedicine (Baltimore)
May 2019
Oncology of Panyu Central Hospital, Panyu Cancer Institute.
Background: Melanoma-associated antigen-A (MAGE-A) was recognized as high-expressed in many solid tumors including esophageal carcinoma (EC), nevertheless, was reported to be low/not-expressed in normal tissues. Thus, it was considered as an extraordinary appropriate target for treatment especially in immunotherapy. Therefore, it demanded more detail knowledge on the precise function of MAGE-A.
View Article and Find Full Text PDF